Overstock.com, Inc. (NASDAQ: OSTK) can't seem to make money selling chatchkes online, so the company has shifted its business model toward suing anyone and everyone who has ever thought a negative though about Overstock, its business model, or its controversial CEO Patrick Byrne.
Today the company announced that it has settled its lawsuit against Gradient Analytics, which it had sued for publishing negative research that played a role in driving down the company's stock price. In a press release issued by Overstock, Gradient said that "Having reviewed all SECfilings, relevant accounting literature, and all other information available to it, Gradient now believes that, to the best of its knowledge, Overstock's stated accounting policies did in fact conform with Generally Accepted Accounting Principles (GAAP) and regrets any prior statements to the contrary."
The company also said that directors it had previously suggested were not independent were in fact independent in accordance with NASD rules.
Is this a big victory for Overstock or just the end of a battle of attrition where the publicly-traded company had more cash to burn on legal fees than the small research shop? We'll never know.
But I'll make a bet right now: Overstock's earnings report for the fourth quarter will not include a massive one-time gain on the settlement of this litigation.
As for Gradient's most important claim -- that Overstock's business model is flawed and the company is unlikely to ever become solidly profitable -- there is no evidence to the contrary.
Last updated: February 07, 2012: 11:20 PM
Hot Stocks
DailyFinance Headlines
- Walgreen's Helps Make Fertility a Men's Issue, Too
- Ford Can't Seem to Take a Joke, but It's Not the End of the World
- Would You Pay $1,499 for an Apple Television?
- Micron CEO's Sudden Death Raises Wider Questions on Corporate Successions
- Bank Fee Backlash Cost Big Financial Institutions More Than 2 Million Customers
Benzinga Headlines
- Theorem's Jay Kulkami Talks Shop with Benzinga
- Energy Independence on the Horizon? Two Companies to Consider
- Powering Up: It Might Be 2010 All Over Again For Lithium ETF
- The Real Deal on Wall Street: Can Dunkin Brands Get a Little Love, Please?
- Are Poor Results From UBS A Bad Omen For Europe?
TheFlyOnTheWall.com Headlines
- CIFC Corp. sells non-core assets for $36.5M
- Harvard Bioscience acquires business of AHN Biotechnologie through subsidiary
- Timken and United Steelworkers Local 1123 announce tentative agreement
- Consolidated Graphics increases share repurchase program to $170M from $100M
- Consolidated Graphics sees Q1 revenue $265M-$275M vs. consensus $265.60M
BioHealth Investor Headlines
- Can Human Genome Really Double Its Stock Price? (HGSI)
- Alimera Implosion Analysis, What Is Next (ALIM, PSDV)
- Implosion Analysis For Targacept… What Lies Ahead? (TRGT, AZN)
- Rare Analyst Calls With Huge Upside in Vical and VIVUS (VICL, VVUS, BMY)
- Top Biotechs With Upside Ahead of Earnings (GILD, AMLN, ARIA, INCY, JAZZ, DNDN, HGSI, ILMN, AMGN, CELG, BIIB, BMRN, LIFE, REGN, AMLN, CBST, ONXX, THRX, VPHM)
WalletPop Headlines
- Walgreen's Helps Make Fertility a Men's Issue, Too
- Ford Can't Seem to Take a Joke, but It's Not the End of the World
- Would You Pay $1,499 for an Apple Television?
- Micron CEO's Sudden Death Raises Wider Questions on Corporate Successions
- Bank Fee Backlash Cost Big Financial Institutions More Than 2 Million Customers
My Portfolios
Track your stocks here!
Find out why more people track their portfolios on AOL Money & Finance then anywhere else.
BloggingStocks Partners
More from AOL Money & Finance
- Business News
- Stock Screener
- Stock Quotes
- Stock Charts
- Banking
- Identity Theft
- DJIA
- Debt Management
- Loans
- Auto Loan
- Mortgages
- Taxes
- Retirement
- Insurance
- Small Business
- Earnings
- Tech News
- Tax Forms
- Tax Deductions
- Tax Credit
- Tax Audit
- Tax Advice
- Stock Ticker
- Stock Brokers
- Resume Builder
- Pig Flu
- Online Tax Filing
- Madoff
- Investing For Retirement
- Income Tax
- Historical Stock Prices
- GOOG
- ETF Investing
- Deals
- DailyFinance
- Crude Oil Prices
- Credit Score Calculator
- Common Tax Filing Mistakes
- AMT
BioHealth Investor Headlines
- Can Human Genome Really Double Its Stock Price? (HGSI)
- Alimera Implosion Analysis, What Is Next (ALIM, PSDV)
- Implosion Analysis For Targacept… What Lies Ahead? (TRGT, AZN)
- Rare Analyst Calls With Huge Upside in Vical and VIVUS (VICL, VVUS, BMY)
- Top Biotechs With Upside Ahead of Earnings (GILD, AMLN, ARIA, INCY, JAZZ, DNDN, HGSI, ILMN, AMGN, CELG, BIIB, BMRN, LIFE, REGN, AMLN, CBST, ONXX, THRX, VPHM)
Savings Experiment: Tissues vs. Toilet Paper
Wrecks to Riches: Hunting Sunken Treasures from Cape Cod to the Costa…

